| INTRODUCTION
Within recent years, robust genome wide approaches have been introduced for non invasive prenatal testing (NIPT) on maternal plasma samples. While these tests are strictly designed to detect fetal trisomies 13, 18, and 21, they also allow detection of subchromosomal fetal imbalances or mostly acquired copy number variations (CNV) in the mother. Over the past 3 years, several caseseries have reported rare incidental findings (IFs) of unique patterns in NIPT of nonspecific multiple chromosomal CNV leading to the diagnosis of previously occult maternal malignancies by NIPT (lymphoma, leukaemia, ovarian, colorectal, anal, and neuroendocrine carcinoma and leiomyosarcoma) during the pregnancy or the weeks following the pregnancy. [1] [2] [3] Controversy remains over whether such an early diagnosis and treatment in a presymptomatic or early stage lead to better survival. 4 Management of unexpected findings of NIPT is a critical issue which is just starting to be addressed by scientific societies.
We report the case of a 40-year-old pregnant woman, without any medical history, offered NIPT because of her age at 12 weeks gestational age (WGA). Her regular gynecologist provided pretest counseling during a routine first-trimester prenatal consultation.
This consisted of oral background information about NIPT without mentioning potential IFs. The patient was provided with a detailed written factsheet developed by the Hospital Genetics Center which performed the test. She signed an informed consent form stating that NIPT can also rarely detect fetal chromosomal abnormalities other than trisomies 21 and 18 and maternal chromosomal anomalies.
The NIPT procedure used a protocol of massive parallel sequencing of cell-free DNA (cfDNA), enabling genome-wide identification of segmental aneuploidies (of fetal or maternal origin). 2, 5 A strongly abnormal genome-wide representation (GR) profile was detected with several subchromosomal imbalances (gains and losses) involving 7 autosomal chromosomes ( Figure 1, left panel) . These extensive CNVs were suggestive of maternal acquired chromosomal imbalances, in particular multiple myeloma (MM), based on gain of 1q, 3, 15, and loss of 13. 6 The patient did not have signs or symptoms suggestive of disease at that time (15 WGA). The gynecologist announced the incidental maternal cancer suspicion to the patient, and further diagnostic and staging investigations were undertaken showed 8% plasma cells (PC), with areas with up to 22% PC.
aCGH and FISH on CD138+ sorted BM PC revealed somatic acquired CNVs, replicating those detected by NIPT, and loss of chromosome X (sex chromosome abnormalities were excluded from NIPT report to comply with national best practice). FISH and cytogenetic examination on CD138+ sorted BM PC confirmed amplification of segment 1q21 in 87% cell nuclei ( Figure 1 ) and in addition revealed the translocation t(4;14)(p16;q32) involving FGFR3
and IGH genes in 77% cell nuclei.
In the absence of hypercalcemia, renal failure, anemia or osteolytic lesions, close clinical, hematological, and biological follow-up was scheduled. At last examination (19 months elapsed from diagnosis), no clinical evolution had occurred, and whole-body PET-CT scanning was negative.
In addition to consultations specifically dedicated to malignancy From being first informed of the abnormal GR profile and the possibility of a maternal malignancy, the patient developed a psychological disorder comparable to general anxiety disorders and required psychological assistance.
Three exceptional NIPT cases have previously been reported revealing abnormalities that led to a diagnosis of maternal cancer. [1] [2] [3] To the best of our knowledge at the time of writing, this is the first NIPT result leading to a diagnosis of MM in the mother. The expected cancer rate is 1 in 1000 pregnancies with hematological malignancies ranked second in tumor type distribution, and given that more than two million NIPTs have been carried out so far, it may be surprising that more cases have not been reported. 8 Nevertheless, MM was highly unexpected in this pregnant woman as the MM incidence in 40 to 49-year-old people is around 2 per 100 000 person-years.
According to the latest revision of guidelines stating criteria for the diagnosis and management of MM, 9 this case should be diagnosed as MM requiring therapy. The FLC Lambda/Kappa ratio of more than 100 is a myeloma defining event because it is regarded as a strong predictive factor of imminent progression to organ damage (in particular renal failure) and to active MM, particularly given the high risk factors such as translocation t(4;14). Therefore, this IF is medically relevant as this condition at least constitutes a strong indication for close monitoring.
The issues of potential lead-time bias and of potential harm to the patient, as well as potential harm to the fetus, are important when the diagnosis of malignancy is made during pregnancy. These issues are still highly contentious, and the decision whether to treat or not will depend on the expected natural history of the disease and the therapy required. Recent data suggest that certain therapies can be given safely during pregnancy, that the maternal outcome can improve, and that the neonatal outcome is normal. 7 This report highlights 2 issues. First, as NIPT is performed to rule out fetal trisomies, abnormal NIPT results almost routinely lead to amniocentesis before a malignant maternal cause is considered.
However, strongly abnormal GR profiles with multiple abnormalities are considered incompatible with normal fetal development. Hence, a normal fetal development for gestational age likely points to a non-fetal origin. In this respect, the amniocentesis performed as the follow-on step could be considered as medically unnecessary.
However, in this situation, the presence of large amounts of "malignant cell" derived cfDNA in the plasma may dilute the fetal cfDNA and obscure a fetal trisomy. Therefore, in this case, even though the results were likely due to a maternal reason, an amniocentesis should be considered.
Second, it is crucial to provide thorough, prior information to patients about the possible IFs. As recently recommended in the literature, 10 we advocate enrichment of this information, enabling pregnant patients undergoing NIPT to choose whether they want to be informed of abnormal unexpected results or not after appropriate pre-test counseling. We suggest that pre-test counseling specifically discuss the points detailed in Table 1 .
What is already known about this subject?
• Non invasive prenatal testing for fetal trisomies 13, 18, and 21 occasionally identifies maternal cancer.
What does this study add?
• A further case of maternal cancer incidentally diagnosed by routine NIPT.
• Extensive NIPT abnormalities are unlikely to be of fetal origin.
• Information given to patients should also adequately advise patients on potential incidental findings and might offer the option to opt out of receiving results beyond the trisomy report.
• International guidelines would improve patient counseling.
It could be argued that strictly limiting testing to main fetal aneuploidies would prevent detection of difficult-to-manage discordant results. However, incidental detection of maternal diseases is almost unavoidable. With a targeted test, for instance, loss of chromosome 13 alone would have been sufficient to raise concern and probably have led to an amniocentesis. Genome-wide profiling may distinguish a tumor profile from a false positive fetal aneuploidy. NIPT frequency is expected to be in the range of one in a thousand to one in ten thousand. 2, 3 Hence, IFs of maternal cancer by NIPT might be more frequent than those by MSS and/or POS. Furthermore, it potentially encompasses a broader spectrum of tumor types.
As NIPT is taking the center stage in prenatal testing, thoughtful guidelines should be implemented, together with better practitioner and patient education. Without guidelines, NIPT might lead to inappropriate medical practice, disrespectful of the priority duties not to harm and to maintain patients' informed and free choice.
